Tetratherix Ltd (TTX) - Net Assets
Based on the latest financial reports, Tetratherix Ltd (TTX) has net assets worth AU$24.37 Million AUD (≈ $17.24 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$38.06 Million ≈ $26.93 Million USD) and total liabilities (AU$13.68 Million ≈ $9.68 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Tetratherix Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$24.37 Million |
| % of Total Assets | 64.04% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Tetratherix Ltd - Net Assets Trend (2023–2025)
This chart illustrates how Tetratherix Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Tetratherix Ltd market capitalisation.
Annual Net Assets for Tetratherix Ltd (2023–2025)
The table below shows the annual net assets of Tetratherix Ltd from 2023 to 2025. Also explore TTX net assets growth trend to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$27.25 Million ≈ $19.28 Million |
+502.05% |
| 2024-06-30 | AU$-6.78 Million ≈ $-4.80 Million |
-48.75% |
| 2023-06-30 | AU$-4.56 Million ≈ $-3.22 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Tetratherix Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1351562000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$47.20 Million | 173.25% |
| Total Equity | AU$27.25 Million | 100.00% |
Tetratherix Ltd Competitors by Market Cap
The table below lists competitors of Tetratherix Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jeju Air Co Ltd
KO:089590
|
$237.25 Million |
|
Kardemir Karabuk Demir Celik Sanayi ve Ticaret AS Class A
IS:KRDMA
|
$237.35 Million |
|
Investar Holding Corp
NASDAQ:ISTR
|
$237.39 Million |
|
Waffer Technology Corp
TW:6235
|
$237.44 Million |
|
Astarta Holding N.V.
WAR:AST
|
$237.06 Million |
|
SITKA GOLD CORP
F:1RF
|
$236.82 Million |
|
Pacific Current Group Ltd
AU:PAC
|
$236.80 Million |
|
Jantsa Jant Sanayi ve Ticaret AS
IS:JANTS
|
$236.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tetratherix Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -6,777,020 to 27,246,870, a change of 34,023,890.
- Net loss of 9,425,550 reduced equity.
- Share repurchases of 24,998,400 reduced equity.
- New share issuances of 24,998,400 increased equity.
- Other factors increased equity by 43,449,440.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-9.43 Million | -34.59% |
| Share Repurchases | AU$25.00 Million | -91.75% |
| Share Issuances | AU$25.00 Million | +91.75% |
| Other Changes | AU$43.45 Million | +159.47% |
| Total Change | AU$- | % |
Book Value vs Market Value Analysis
This analysis compares Tetratherix Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.19x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-06-30 | AU$-0.09 | AU$6.60 | x |
| 2024-06-30 | AU$-0.13 | AU$6.60 | x |
| 2025-06-30 | AU$0.54 | AU$6.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tetratherix Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -34.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -824.89%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.17x
- Recent ROE (-34.59%) is below the historical average (-11.53%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | 0.00% | -321.48% | 0.41x | 0.00x | AU$-1.36 Million |
| 2024 | 0.00% | -295.72% | 0.61x | 0.00x | AU$-1.88 Million |
| 2025 | -34.59% | -824.89% | 0.04x | 1.17x | AU$-12.15 Million |
Industry Comparison
This section compares Tetratherix Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $10,385,707
- Average return on equity (ROE) among peers: -31.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tetratherix Ltd (TTX) | AU$24.37 Million | 0.00% | 0.56x | $237.07 Million |
| Adalta Ltd (1AD) | $10.62 Million | -10.96% | 0.01x | $5.41 Million |
| Algorae Pharmaceuticals Ltd (1AI) | $4.14 Million | -76.87% | 0.39x | $12.88 Million |
| ACRUX Ltd (ACR) | $17.49 Million | -17.99% | 0.05x | $2.91 Million |
| Actinogen Medical Ltd (ACW) | $1.05 Million | -70.96% | 0.09x | $130.32 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $13.63 Million |
| Arovella Therapeutics Ltd (ALA) | $8.84 Million | -33.96% | 0.88x | $50.46 Million |
| Anatara Lifesciences Ltd (ANR) | $-96.00K | 0.00% | 0.00x | $1.57 Million |
| Alterity Therapeutics Ltd (ATH) | $15.78 Million | -28.97% | 0.04x | $108.75 Million |
| Amplia Therapeutics Ltd (ATX) | $3.19 Million | -101.84% | 0.80x | $45.40 Million |
| Avecho Biotechnology Ltd (AVE) | $28.90 Million | 60.97% | 0.19x | $54.68 Million |
About Tetratherix Ltd
Tetratherix Limited engages in biomaterial and regenerative medicine business in Australia and internationally. The company manufactures and commercialize medical device in the areas of bone regeneration, tissue spacing, and tissue healing applications through its Tetramatrix platform technology. Tetratherix Limited was incorporated in 2015 and is based in Alexandria, Australia.